Does anybody have any concepts for compounds, or mixtures, that they’re contemplating sending in to the ITP program for testing (or have already despatched in?).
I’m questioning if this new discovery would possibly warrant a proposal? Examine: Medication Revitalizing Outdated Blood Could Sluggish Getting older
Software Directions
The submission deadline happens as soon as per yr on the final weekday in February.
The subsequent deadline is Tuesday, Feb. 28, 2023.
See Software Directions and use the Software Kind (Phrase, 32K).
Request for Proposals
NIA seeks proposals for brokers to be included in Stage I testing to find out results on lifespan. Interventions can embrace, however should not restricted to, prescribed drugs, nutraceuticals, dietary dietary supplements, plant extracts, hormones, peptides, amino acids, chelators, redox brokers, and mixtures of compounds. All take a look at brokers should be capable to be stably integrated into rodent chow. Candidates will be people, nonprofit or educational teams, or industrial entities. NIA is liable for the prices of the testing by grants to the three testing websites.
Purposes that don’t conform to this requirement could also be returned with out evaluation. Though there isn’t any size restrict, most purposes are between 5 and 10 pages lengthy.
Examples of Profitable Proposals
Instance 1 – MIF098 (PDF, 296 KB)
Instance 2 – Resveratrol (PDF, 200 KB)
Instance 3 – Sulindac (Phrase, 178 KB)
Instance 4 – mTOR Inhibitors (Phrase, 227 KB)
Software Directions:
Extra info: ITP | Nationwide Institute on Getting older
Associated, Good Video on the NIA ITP Program: Medication That Sluggish Getting older in Mice: the NIA Interventions Testing Program
1 Like
Rapamycin + A potent ldl cholesterol discount drug like a statin + Acarbose
To attenuate the unfavorable results of Rapamycin on ldl cholesterol (statin) and blood sugar (acarbose).
Nevertheless, mice don’t die of CVD, so perhaps reserve it for the human trials. 
1 Like
Undoubtedly warrants a proposal. Is it injectable solely although?
